GlassScriptPhysician profile
Ahmer Ali
NPI 1275825978
$14,956.49
in general payments reported to CMS, 2019-2025
58 companies · $3,691 in 2025
The $3,691 reported for 2025 was more than what 85% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $885 · 2021: $2,658 · 2022: $2,029 · 2023: $2,152 · 2024: $2,876 · 2025: $3,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,369 · Education: $200 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,369.05 |
| Education | $199.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,813.06 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $1,481.50 | 2023-2025 | |
| Harmony Biosciences LLC | $1,279.56 | 2021-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $815.02 | 2019-2022 | |
| Ucb, INC. | $765.25 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Lilly USA, LLC | $714.48 | 2021-2025 | Kisunla, Emgality, Amyvid |
| Biohaven Pharmaceuticals, INC. | $595.56 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $544.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $436.06 | 2019-2025 | |
| Tg Therapeutics, INC. | $431.92 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $419.77 | 2019-2025 | |
| Amgen INC. | $391.29 | 2019-2024 | Aimovig |
| Inspire Medical Systems, INC. | $266.05 | 2024 | Inspire |
| Neurocrine Biosciences, INC. | $262.23 | 2020-2025 | Ingrezza |
| Argenx US, INC. | $215.55 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmer Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.